Back to Blog

AREDS2 Formula: Understanding the Eye Supplement That Reduces AMD Progression

February 19, 2026·4 min read

The AREDS2 formula is one of the most rigorously studied supplement regimens in ophthalmology. Unlike most eye supplements marketed on vague claims, this exact combination was tested in a large, government-funded randomized controlled trial and shown to meaningfully reduce the progression of age-related macular degeneration (AMD) in specific patients. Understanding the formula — and who it is and is not intended for — matters before spending money on it.

What the AREDS2 trial was

The Age-Related Eye Disease Study 2 was a multicenter, randomized clinical trial conducted by the National Eye Institute involving over 4,000 participants across the United States. It ran for a median of five years and tested modifications to the original AREDS formula, most importantly replacing 15mg beta-carotene with 10mg lutein + 2mg zeaxanthin after data emerged linking high-dose beta-carotene to elevated lung cancer risk in former smokers.

The exact AREDS2 formula

The formula tested and validated in the trial contains:

  • Vitamin C: 500mg
  • Vitamin E: 400 IU (as dl-alpha-tocopheryl acetate)
  • Lutein: 10mg
  • Zeaxanthin: 2mg
  • Zinc: 80mg (as zinc oxide)
  • Copper: 2mg (as cupric oxide)

The copper is included specifically to prevent copper-deficiency anemia that can result from the high zinc dose. Do not take the full zinc dose without the copper.

Why beta-carotene was removed

The original AREDS formula included 15mg beta-carotene, a provitamin A carotenoid. Subsequent analysis of AREDS data, combined with earlier trials (the CARET trial and the Finnish ATBC trial), showed that former smokers taking beta-carotene supplements had a 28% higher risk of lung cancer compared to those who did not. The AREDS2 substitution to lutein and zeaxanthin eliminated this risk while actually improving outcomes — the lutein/zeaxanthin group showed a 25% lower risk of AMD progression compared to the beta-carotene group.

If you are a former smoker, look specifically for AREDS2 formulas that are beta-carotene free.

Who qualifies for AREDS2

This formula is indicated for patients with:

  • Intermediate AMD in one or both eyes (defined by medium-sized drusen or one large druse in one eye)
  • Advanced AMD (geographic atrophy or neovascular/wet AMD) in one eye, to protect the other eye

It is not indicated for:

  • People with early AMD only (small drusen, no pigment changes)
  • People with no signs of AMD
  • People using it as general preventive nutrition

The trial enrolled patients at high risk for progression — not healthy individuals — and the benefits observed apply specifically to that population. Using it without a diagnosis wastes money and exposes you to unnecessary high-dose zinc.

The PreserVision connection

PreserVision AREDS 2 (Bausch + Lomb) is the most commonly recommended brand because it was the formula used in the clinical trial. When ophthalmologists recommend the AREDS2 formula, they typically specify this brand to ensure dose accuracy. Generic equivalents with matching doses can also be appropriate, but verify the exact milligrams.

Zinc and copper balance

The 80mg zinc dose in AREDS2 is substantially higher than the daily RDA for zinc (8–11mg for adults). At this dose, zinc competes with copper absorption in the gut, which can lead to copper-deficiency anemia over time — a serious condition affecting red blood cells and neurological function. The inclusion of 2mg copper in the formula addresses this directly.

Do not supplement with high-dose zinc in other products while taking AREDS2, as this compounds the copper-depletion risk.

Ophthalmologist consultation is required

AMD staging requires dilated fundus examination by an eye care professional. Drusen size, location, and the presence of pigment changes determine whether you have early, intermediate, or advanced AMD. This cannot be self-assessed, and starting AREDS2 supplements without a diagnosis is not justified by the evidence.

Annual dilated eye exams are recommended for everyone over 50, and more frequently once AMD is diagnosed.

Limitations of the formula

AREDS2 reduces the rate of progression in high-risk patients — it does not reverse existing AMD or restore lost vision. Patients with wet AMD require anti-VEGF injection treatment alongside monitoring. The supplements address one piece of AMD management, not the whole picture.

The bottom line

The AREDS2 formula is among the most evidence-based supplement regimens in medicine, validated in a large RCT to reduce AMD progression by 25% in the right patients. But it is a clinically indicated treatment for a specific diagnosed condition — not a general eye vitamin for healthy people.


If you have AMD or related eye health concerns and want to organize your supplement regimen around the evidence, Use Optimize free.

Related Articles

Want to optimize your health?

Create your free account and start tracking what matters.

Sign Up Free